These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

924 related articles for article (PubMed ID: 33788704)

  • 1. T-cell-based Immunotherapies for Haematological Cancers, Part A: A SWOT Analysis of Immune Checkpoint Inhibitors (ICIs) and Bispecific T-Cell Engagers (BiTEs).
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1123-1141. PubMed ID: 33788704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-cell-based Immunotherapies for Haematological Cancers, Part B: A SWOT Analysis of Adoptive Cell Therapies.
    Rallis KS; Hillyar CRT; Sideris M; Davies JK
    Anticancer Res; 2021 Mar; 41(3):1143-1156. PubMed ID: 33788705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting immune checkpoints in hematological malignancies.
    Salik B; Smyth MJ; Nakamura K
    J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies.
    Tian Z; Liu M; Zhang Y; Wang X
    J Hematol Oncol; 2021 May; 14(1):75. PubMed ID: 33941237
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel immunotherapies for hematologic malignancies.
    Nelson MH; Paulos CM
    Immunol Rev; 2015 Jan; 263(1):90-105. PubMed ID: 25510273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model.
    Ma H; Wang H; Sové RJ; Wang J; Giragossian C; Popel AS
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32859743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Infectious events in patients treated with immune checkpoint inhibitors, chimeric antigen receptor T cells, and bispecific T-cell engagers: a review of registration studies.
    Lombardi A; Saydere A; Ungaro R; Bozzi G; Viero G; Bandera A; Gori A; Mondelli MU
    Int J Infect Dis; 2022 Jul; 120():77-82. PubMed ID: 35429642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The State of Immunotherapy in Hepatobiliary Cancers.
    Ilyas FZ; Beane JD; Pawlik TM
    Cells; 2021 Aug; 10(8):. PubMed ID: 34440865
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining Oncolytic Viruses With Cancer Immunotherapy: Establishing a New Generation of Cancer Treatment.
    Shi T; Song X; Wang Y; Liu F; Wei J
    Front Immunol; 2020; 11():683. PubMed ID: 32411132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Advances in Immunotherapies for Hematological Malignancies.
    Nogami A; Sasaki K
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors affecting tumor responders and predictive biomarkers of toxicities in cancer patients treated with immune checkpoint inhibitors.
    Yao L; Jia G; Lu L; Bao Y; Ma W
    Int Immunopharmacol; 2020 Aug; 85():106628. PubMed ID: 32474388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison.
    Cheng L; Chen L; Shi Y; Gu W; Ding W; Zheng X; Liu Y; Jiang J; Zheng Z
    Mol Cancer; 2024 Apr; 23(1):77. PubMed ID: 38627681
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
    Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
    Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance.
    Bagchi S; Yuan R; Engleman EG
    Annu Rev Pathol; 2021 Jan; 16():223-249. PubMed ID: 33197221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The swinging pendulum of cancer immunotherapy personalization.
    Abraham TS; Snook AE
    Per Med; 2017 May; 14(3):259-270. PubMed ID: 29767586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunomodulatory Precision: A Narrative Review Exploring the Critical Role of Immune Checkpoint Inhibitors in Cancer Treatment.
    Qiu J; Cheng Z; Jiang Z; Gan L; Zhang Z; Xie Z
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer Immunotherapy - Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Bai J; Liang P; Li Q; Feng R; Liu J
    Recent Pat Anticancer Drug Discov; 2021; 16(2):239-248. PubMed ID: 33583384
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade.
    Jeong S; Park E; Kim HD; Sung E; Kim H; Jeon J; Kim Y; Jung UJ; Son YG; Hong Y; Lee H; Lee S; Lim Y; Won J; Jeon M; Hwang S; Fang L; Jiang W; Wang Z; Shin EC; Park SH; Jung J
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34230109
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Recent advances of immunooncology in the treatment of solid tumours and haematological malignancies: the immune checkpoint inhibitors].
    Fésüs V
    Magy Onkol; 2017 Jun; 61(2):116-125. PubMed ID: 28585612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.